Key features and details | |
Cat. No. | MABL-738 |
Name | Anti-CD16 mAbs |
Clone No. | AFD- NM3E2 |
From | Recombinant Antibody |
Isotype | Engineer antibody |
Application | ELISA, FC |
Species Reactivity | Human |
Basic Information | |
Specificity | This antibody binds the extracellular domain of human CD16. This antibody recognizes an epitope in the vicinity of the Fc binding pocket. CD16, also known as FcγRIII, is a cluster of differentiation molecule found on the surface of natural killer cells, neutrophils, monocytes, macrophages, and certain T cells. CD16 has been identified as Fc receptors FcγRIIIa (CD16a) and FcγRIIIb (CD16b), which participate in signal transduction. |
Alternative Name | CD16a; CD16b; FCGR3; FCGR3A; FCGR3B; FcγRIII; Fc-gamma RIII-alpha; Fc-gamma RIII; Fc-gamma RIIIa; FcRIII; FcRIIIa; FcR-10; IgG Fc receptor III-2; Fc-gamma RIII-beta; Fc-gamma RIIIb; FcRIIIb; Low affinity immunoglobulin gamma Fc region receptor III; Low affinity immunoglobulin gamma Fc region receptor III-A; Low affinity immunoglobulin gamma Fc region receptor III-B |
UniProt | P08637 |
Immunogen | The original antibody was isolated from a human scFv phage display library by panning against human CD16. |
Application Notes | This antibody is recommended for use in the generation of bispecific antibodies. The binding affinity of this antibody to human CD16 was determined using ELISA and surface plasmon resonance. The original scFv antibody binds human CD16 with an affinity of Kd= 0.2 nM. This antibody in combination with anti-HER2 antibody C6.5 was used in the generation of a bispecific antibody bsAb 2B1, which targets the extracellular domains (ECD) of the HER2/neu protooncogene product and the human FcgammaRIII or CD16. In the presence of the C6.5 x NM3E2 bs-scFv, peripheral blood lymphocytes promoted significant lysis of human SK-OV-3 ovarian cancer cells overexpressing HER2/neu (PMID：10449096). This antibody was also used in the generation of a heterodimeric bispecific scFv antibodies against EpCAM and CD16. This bispecific antibody was reported to enhance the killing of human carcinomas of the prostate, breast, colon, head, and neck even at very low effector target ratios (PMID： 23611188). |
Antibody First Published | McCall et al. Isolation and characterization of an anti-CD16 single-chain Fv fragment and construction of an anti-HER2/neu/anti-CD16 bispecific scFv that triggers CD16-dependent tumor cytolysis. Mol Immunol. 1999 May;36(7)：433-45. PMID：10449096 |
Note on publication | The paper describes the isolation, characterization of an anti-CD16 scFv antibody and its use in the generation of a bispecific antibody. |
COA Information （For reference only, actual COA shall prevail） | |
Size | 100 μg Purified antibody. |
Concentration | 1 mg/ml. |
Purification | Protein A affinity purified |
Buffer | PBS with 0.02% Proclin 300. |
Concentration | 1 mg/ml. |
Storage Recommendation | Store at 4⁰C for up to 3 months. For longer storage, aliquot and store at - 20⁰C. |
